Chronic Myeloid Leukemia-Transplantation in the Tyrosine Kinase Era
Chronic Myeloid Leukemia-Transplantation in the Tyrosine Kinase Era
复制标题
DOI：
10.1016/j.hoc.2014.08.002
复制
发表时间：
2014-12-01
影响因子：
2.4
通讯作者：
Apperley, Jane F.
中科院分区：
文献类型：
--
作者：
Innes, Andrew J.;Apperley, Jane F.
在20世纪80年代，异基因造血干细胞移植（HSCT）彻底改变了许多慢性髓性白血病（CML）患者的前景。近15年前，酪氨酸激酶抑制剂（TKIs）的引入取代了HSCT，成为大多数CML患者的一线治疗方法。然而，在21世纪，HSCT仍然是许多CML患者可行的治疗选择。这篇综述的重点是在TKI时代HSCT治疗CML的作用，特别关注患者选择和移植结果。
Allogeneic hematopoietic stem cell transplantation (HSCT) revolutionized the outlook for many patients with chronic myeloid leukemia (CML) in the 1980s. The introduction of the tyrosine kinase inhibitors (TKIs) nearly 15 years ago displaced HSCT as the first-line treatment for most CML patients. However, in the twenty-first century HSCT remains a viable treatment option for many patients with CML. This review focuses on the role of HSCT for CML in the TKI era, paying particular attention to patient selection and transplant outcome.